Logo

Nucleix: Michael Vicari

Jun 06, 2023

Nucleix, a Rehovot, Israel-based liquid biopsy company, has appointed Michael Vicari as chief commercial officer to lead commercialization efforts for the firm's Lung EpiCheck blood test for early lung cancer. Vicari joins Nucleix from Grail, where his team launched the Galleri multi-cancer early detection assay. Prior to Grail, Vicari held senior level commercial positions at Inivata, OncoCyte, Sequenom, Monogram Biosciences, and Genentech.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.